- Email: [email protected]
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy
Saudi Pharmaceutical Journal (2013) xxx, xxx–xxx
King Saud University
Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com
REVIEW
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy Regin Elsa George, Siby Joseph
*
Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India Received 8 April 2013; accepted 17 May 2013
KEYWORDS Gliptins; Dipetidyl peptidase inhibitors; Glucagon like peptide
Abstract Diabetes resulting from both genetic and lifestyle factors causes high insulin deficiency or its resistance. As hyperglycemia and decreased insulin secretion and/or its sensitivity appear to be the primary defects associated with diabetes, available treatments focus on reducing those defects. A novel approach of treatment is to target the incretin mimetic hormones, which are secreted by intestinal cells in response to food intake, provoking glucose-dependent insulin secretion from the pancreas. Efficacy and safety studies of dipetidyl peptidase inhibitors (DPP-IV), sitagliptin, vildagliptin and linagliptin provide similar improvements in HbA1c levels when compared with metformin, sulfonylureas or glitazones without contributing to weight gain and hypoglycemia. Caution is required when choosing the gliptin in people with renal or hepatic impairment and with a risk of pancreatitis. The glucagon like peptide (GLP-1) analogues Exenatide and Liraglutide also have positive impact on glycemic control especially when used as a combination therapy. Another upcoming approach is using sodium-glucose co transporter two inhibitors in kidney, by exploring pathophysiology of renal glucose re absorption in the proximal tubule. ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Introduction Even though diabetes is not a new born disease with a history since 1552 its prevalence is increasing day by day. As in other * Corresponding author. Tel.: +91 9961312691. E-mail address: [email protected] (S. Joseph). Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
diseases newer drugs are getting added up and some become outdated or withdrawn. Even the most commonly used oral hypoglycemic agent (OHA) metformin is found to be ineffective in the long-term therapy for many patients. Sulfonylureas are used in case of patients who are not responding to metformin. But they can put patients at an increased risk of hypoglycemia, weight gain, heart attacks and strokes. Glitazones are also associated with cardiovascular risks. To avoid such pitfalls and to improve glycemic control with minimum side effects new therapeutic approaches are developed. Dipeptidyl peptidase (DPP)-4 inhibitors, which enhance postprandial levels of the incretin hormones glucagon like peptide (GLP)-1
1319-0164 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. http://dx.doi.org/10.1016/j.jsps.2013.05.005
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
2 and glucose-dependent insulinotropic polypeptide (GIP), are newer therapeutic options with minimal side effects (Dicker, 2011). The revised consensus algorithm accounts for the introduction of incretin-based therapies into clinical practice. The algorithm was authored in 2009 by the American Diabetes Association and European Association for the Study of Diabetes for the initiation and adjustment of therapy in Type 2 diabetes. The incretin hormones are gut borne and have clinically meaningful effects on glucose homeostasis, particularly in the postprandial period. So according to the algorithm their use can be emphasized in cases of hypoglycemia and increased body weight. Also 66% of the b-cell response during post prandial period is due to the incretin effect. The foundation of incretin-based therapies is to target this newly recognized feature of diabetes pathophysiology, resulting in sustained and powerful glycemic control and body weight control (Stonehouse et al., 2012; McIntosh et al., 2005). The incretins are peptide hormones released into the circulation, in response to luminal nutrients, minutes after a meal. In humans, the major incretins are glucagon-like peptide-1 (GLP-1) secreted by the L cells in the ileum and colon and glucose-dependent insulinotropic polypeptide (GIP) secreted by the K cells in the duodenum. Hormonal effects on multiple organs are found to be exhibited by both GLP-1 and GIP and stimulate insulin secretion in a glucose-dependent manner along with appetite suppression and delayed gastric emptying. As a result of these combined effects, significant contribution has been made for the control of postprandial glucose resulting in a better glycemic control with relatively low risk of hypoglycemia. (Prins, 2008) The incretins are predominant gut borne mediators of insulin release, and GLP-1 deals with glucagon suppression. GLP-1 represents a clinically better therapeutic option over GIP as its insulinotropic effects are preserved in type 2 DM while GIP activity is impaired (Fujioka, 2007). However both incretins are rapidly inactivated in vivo by the enzyme DPP-IV. Two approaches considered to enhance the incretin effect in type 2 diabetes are to either administer GLP-1 receptor agonists that are resistant to cleavage by DPP4 or to inhibit DPP4 enzyme activity. These pharmacological approaches thereby effectively increase the half-life and circulating levels of the incretins (Prins, 2008).
R.E. George, S. Joseph are clinically used now, given as subcutaneous injection. Formulation developments are on going to check whether long-acting once-weekly injections are possible. Exendin, the clinical formulation of exenatide is a potent activator of the GLP-1 receptor with almost 50% homology to GLP-1, while liraglutide maintains normal activity at the GLP-1 receptor. Both are resistant to cleavage by DPP4 and have a long circulating half-life (Prins, 2008). Dipeptidyl-peptidase IV inhibitors Dipeptidyl-peptidase (DPP) IV is a ubiquitous enzyme that is responsible for the inactivation of both incretin hormones GLP-1 and GIP. DPP IV inhibitors are FDA approved oral medications in type 2 diabetes, which inhibit dipeptidyl peptidase-4 thereby increase circulating concentrations of incretin hormones and provide glycemic control with improved islet cell function (Pratley and Salsali, 2007) and by this mechanism of action they allow GLP1 to stay in the body for longer time which improves control of glucose as well as reduce appetite. They help the pancreas to secrete insulin in glucose dependent manner in post-prandial period and thereby reducing dramatic episodes of blood sugar spikes (Stonehouse et al., 2012) Also they are well tolerated, carry a low risk of hypoglycemia and weight gain (Stonehouse et al., 2012; Pratley and Salsali, 2007). Another new approach is the use of sodium glucose co transporter-2 inhibitors which are in the phase III studies for the treatment of type 2 diabetes. Several specific SGLT2 inhibitors currently under development include dapagliflozin, canagliflozin, empagliflozin, ipragliflozin and tofogliflozin. They work independently and inhibit glucose re-absorption from the glomerular filtrate. Reduced renal threshold for glucose, glycosuria and net calorie loss are the results. Trials regarding long-term outcomes are ongoing (Isaji, 2007; Grempler et al., 2012). In the present article, we discuss the attributes of new treatment strategies of diabetes and an attempt has been made to compare and elaborate various aspects of incretin based therapies including their efficacy and adverse reactions focused on GLP1 agonists and commonly used gliptins-vildagliptin, Sitagliptin and linagliptin. Comparison of various efficacy studies of Sitagliptin, Vildagliptin and Linagliptin
Incretin-analogue based therapies Glucagon-like peptide 1 (GLP-1) analogues are the foundation of incretin-based therapies and the main advantage is that they can be used as monotherapy, or in combination with other diabetic medications along with diet and exercise in adults with type 2 DM (Chiniwala and Jabbour, 2011) Emerging evidence suggests minimum risk of hypoglycemia with incretin-based treatments except in combination with insulin secretagogues. They also exhibit beneficial effects on cardiovascular and hepatic health, the central nervous system, inflammation and sleep (Stonehouse et al., 2012) The administration of incretin analogues resistant to cleavage by DPP4 was really appreciable. Two drugs exenatide and liraglutide
A large number of clinical studies and extensive clinical experience demonstrate that gliptins provide unique therapeutic benefits that make them ideal for treatment of type 2 diabetes. They are available in combination pills with Metformin. All these medicines have been shown to significantly reduce HbA1c when used as monotherapy and in combination with other traditional agents. But they are comparatively more expensive. Several studies were designed and done to compare these drugs with other OHAs to clarify their efficacy in relation to traditional agents. Various meta analysis were done to study the safety issues also. They are found to be associated with minimum side effects like headache, nausea as well as mild skin reactions.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy
3
Monotherapy Drug
Duration (weeks)
Number of subjects (N) Baseline HbA1c (%)
Reduction in HbA1c (%)
555 743 123 521 741 65
7.7 7.8 7.8 8.1 8 7.7
0.6 0.8 0.7 (Elderly) 0.6 & 0.5, respectively 0.8 & 0.9, respectively 0.6
12 24
70 & 28, respectively 632
8 8.4
24
354
8.4
12 12
279 & 98 291
8 7.4
188 & 192, respectively
7.6
519 & 267, respectively
8.7
0.6 ± 0.2 0.8 ± 0.1,0.8 ± 0.1 & 0.9 ± 0.1, respectively 0.7 ± 0.2, 0.5 ± 0.2 & 0.9 ± 0.2, respectively 0.43 & 0.6, respectively 0.8%, 1.0% & 1.2% respectively (placebo adjusted mean change) <6.5% in 50.8% & 24.2% patients respectively 1.1 & 1.3, respectively
336 & 167, respectively
P 9.0
5 mg OD &10 mg OD vs voglibose 0.2 mg 26 tid (Kawamori et al., 2012)
561
7.63,7.50 & 7.91, respectively
5 mg OD &10 mg OD vs Placebo (Kawamori et al., 2012)
12
–
7.58%, 7.48% and 8.34%, respectively
24
1091
8.8
24
701
8
52
1172
7.5
18
273
7.7
2.07%, 1.57%, 1.30%, 0.99% & 0.83%, respectively (placebo subtracted change) <7% in 47% & 18.3% patients respectively 0.67 in both (63% and 59% patients respectively) 0.7 & 0.8, respectively
24
441
8.3
0.89
Vildagliptin 50 mg OD (Ahren et al., 2004) 12 50 mg OD vs placebo (Ahren et al., 2005) 52
107 31& 26, respectively
7.7 ± 0.1 7.7
50 mg OD & 50 mg BID vs Placebo (Bosi 24 et al., 2007)
n = 177, 185 and 182, respectively
7.5–11%
50 mg BID vs 30 mg OD pioglitazone (Bolli et al., 2008)
295 & 281, respectively
7.5–11%
0.6 ± 0.1 1.0 ± 0.2% (between group difference) 0.7 ± 0.1% & 1.1 ± 0.1%, respectively (between group difference) 0.9 & 1.0, respectively
524 & 177, respectively
8.1
0.49 & +0.15, respectively
777 & 775, respectively
7.69
0.16 & 0.36, respectively
Sitagliptin 100 mg (Hanefeld et al., 2007; Scott et al., 12 2007; Barzilai et al., 2009) 100 mg & 200 mg (Raz et al., 2006) 24 18 100 mg & 200 mg (Aschner et al., 2006) 24 50 mg (moderate renal insufficiency) 54 25 mg (severe insufficiency) (Chan et al., 2008) Vildagliptin 25 mg BD vs Placebo (Pratley et al., 2006) 50 mg BID, 50 mg OD & 100 mg OD (Dejager et al., 2007) 50 mg BID,50 mg OD & 100 mg OD (PiSunyer et al., 2007) 50 mg & 100 mg (Kalra, 2011) 10 mg, 25 mg & 50 mg BID vs Placebo (Kikuchi et al., 2009)
50 mg BID compared with voglibose 12 (Iwamato et al., 2010) 100 mg compared with rosiglitazone 8 mg 24 (Rosenstock et al., 2007a) Linagliptin 5MG vs Placebo (Del Prato et al., 2011) 24
As add on to metformin Sitagliptin 100 mg + metformin 2G BD, 100 mg + metformin 1G BD, metformin 2G BD, metformin 1G BD, 100 mg OD & placebo (Goldstein et al., 2007) 100 mg vs Placebo (Charbonnel et al., 2006) 100 mg vs 5 mg (Glipizide) (Nauck et al., 2007) 100 mg vs 8 mg (Rosiglitazone) (Scott et al., 2008) 100 mg (As add on to metformin + glimepiride) (Hermansen et al., 2007)
24
Linagliptin Compared with Placebo (Taskinen et al., 24 2011) Compared with glimepiride (Gallwitz 2 year et al., 2012a)
1.01% (placebo adjusted reduction) 0.32% & 0.39%, respectively (adjusted mean difference) 0.87% & 0.88% respectively (adjusted mean difference)
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
4
R.E. George, S. Joseph
Monotherapy Drug
Duration (weeks)
Number of subjects (N) Baseline HbA1c (%)
Reduction in HbA1c (%)
333
793 & 265, respectively
8.2%, 8.5%, 8.4%, 8.2%, and 8.4%, respectively 7–10%
0.4,0.73,0.67 & 0.9 respectively (treatment difference vs placebo) 0.72 & 0.1, respectively
6 MONTH
441
8.3
0.7
24
515
7.5–11
0.6 ± 0.1%, & 0.7 ± 0.1%, respectively (between group difference)
161 & 84, respectively
8.6
0.47 (Placebo adjusted change)
175 & 178, respectively
8.1 & 8, respectively
7.2 & 7.8, respectively (HbA1c at end point)
463
8.7
0.8, 1.0 & 0.3, respectively
150 & 157, respectively
8.7
1.1 & 1.4, respectively
146 & 139, respectively
8.7
1.9 & 1.7, respectively
24
259 & 130, respectively
8.6 & 8.58, respectively 1.25 & 0.75, respectively
Body weight Neutral (monotherapy) Increasing (With insulin and sulfonylureas) (Scott et al., 2007; Raz et al., 2006; Rosenstock et al., 2007a; Charbonnel et al., 2006; Hermansen et al., 2007; Arjona Ferreira et al., 2008) Neutral (Bosi et al., 2007; Bolli et al., 2008; Garber et al., 2007; Pratley et al., 2006; Scherbaum et al., 2008; Schweizer et al., 2007) Neutral or decreased (monotherapy) Del Prato et al., 2011; Taskinen et al., 2011; Forst et al., 2010; Owens et al., 2011; Lewin et al., 2010; Kawamori et al., 2011 Increasing (with glitazones) Gomis et al., 2011
Hypoglycemia None (monotherapy) (Barzilai et al., 2009; Raz et al., 2006; Rosenstock et al., 2007a; Rosenstock et al.) Increasing (with insulin and sulfonylureas) (Nauck et al., 2007; Hermansen et al., 2007; Vilsboll et al., 2010)
More reported events Headache, upper respiratory tract infection, nasopharyngitis. (Chan et al., 2008)
Rare events Pancreatitis, hypersensitivity reactions (Ahre´n, 2010)
None (monotherapy) Nausea, headache Increasing (with insulin) nasopharyngitis, Kalra, 2011 dizziness, cough, constipation (Pratley et al., 2006; Scherbaum et al., 2008) Increasing (with insulin, Urticaria, angioedema sulfonylureas and insulin or bronchial secretagogues) (Forst hyperreactivity (Del et al., 2010; Owens et al., Prato et al., 2011; 2011; Lewin et al., 2010; Taskinen et al., 2011; Gallwitz et al., 2011) Forst et al., 2010; Owens et al., 2011; Gomis et al., 2011; Tradjenta, 2011)
Mild liver enzyme elevation (Kothny et al., 2009)
(As add on to metformin ± OAD) 1 mg, 12 5 mg, 10 mg vs Glimepiride (1–3 mg) or Placebo (Forst et al., 2010) (As add on to metformin + sulfonylurea) 24 5 mg vs Placebo (Owens et al., 2011) As add on to sulfonylurea Sitagliptin 100 mg (Hermansen et al., 2007) Vildagliptin 50 mg OD, BID vs 4 mg (Glimepiride + Placebo) (Garber et al., 2008)
Linagliptin 5 mg OD vs Placebo (Lewin et al., 2010) 18 As add on to glitazones Sitagliptin Compared with placebo (Rosenstock et al.)
24
Vildagliptin 50 mg OD, BD vs 45 mg 24 Pioglitazone + Placebo (Garber et al., 2007) 100 mg OD vs 30 mg Pioglitazone OD) 24 (Rosenstock et al., 2007b 100 mg + 30 mg Pioglitazone & 24 50 mg + 15 mg Pioglitazone (Rosenstock et al., 2007b) Linagliptin 5 mg or Placebo (Gomis et al., 2011) Comparison of safety studies Drug Sitagliptin
Vildagliptin
Linagliptin
-
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy EXENATIDE: Exenatide is the first drug that mimics the activity of incretins, the natural glucoregulatory peptides. In April 2005 it was approved by the US FDA as an adjunctive therapy in patients with type 2 diabetes. Exenatide is a subcutaneously injected, peptide GLP-1 receptor agonist that has been shown to improve glycemic control, promote weight loss, and improve some cardiovascular risk markers in patients with T2DM (Klonoff et al., 2008; Aroda and DeYoung, 2011). LIRAGLUTIDE: Liraglutide is another glucagon-like-peptide-1 (GLP-1) receptor agonist, taken as once daily injection. It was approved by FDA on January 25, 2010. It is designed not only to improve 24-h glycemic control in a glucose-
5
dependent manner by increasing insulin secretion and decreasing glucagon secretion (Chang et al., 2003; Degn et al., 2004) but also accompanied by a delay in gastric emptying and weight loss (Juhl et al., 2002). Many researchers have demonstrated that both exenatide and liraglutide are well tolerated and produce clinically meaningful reduction of HbA1c when used alone and in combination with other drugs. Comparison of various efficacy studies of exenatide and liraglutide
Monotherapy Dose
Duration
No. of patients
Reduction in HbA1c (%)
Exenatide 2 mg once weekly vs 100 mg Sitagliptin or 45 mg Pioglitazone (Bergenstal et al., 2012)
26
160, 166 & 165, respectively
0.6 & 0.3, respectively (treatment difference of exenatide vs Sitagliptin or Pioglitazone)
Once weekly vs metformin, pioglitazone and Sitagliptin (Jones et al., 2012)
26
–
1.53, 1.48, 1.63 & 1.15, respectively
Liraglutide 1.2 mg & 1.8 mg vs Glimepiride (Garber et al., 2009) 1.2 mg & 1.8 mg vs Glimepiride 8 mg (Garber et al., 2011) 0.65 mg, 1.25 mg, 1.90 mg & Placebo (Vilsboll et al., 2007)
52 2 year 14
746 – –
0.84%, 1.14% & 0.51%, respectively 0.9, 1.1 & 0.6, respectively 0.98, 1.40, 1.45 & +0.29, respectively
30
377
30
272
30
733
0.86 ± 0.11%, 0.46 ± 0.12%, and 0.12 ± 0.09%, respectively 0.78 ± 0.10, 0.40 ± 0.11 & +0.08 ± 0.10 0.8 ± 0.1, 0.6 ± 0.1 & +0.2 ± 0.1, respectively
26 26
225,221 & 219, respectively 533
1.5% ± 0.1%vs 1.5% ± 0.1%
26
581
1.33% vs 1.09%
26
233 & 231, respectively
1.12% vs 0.79%, respectively
As combination therapy Exenatide 10 lg, 5 lg, and placebo (as add on to sulfonyl urea) (Buse et al., 2004) 10 lg, 5 lg, and placebo (as add on to metformin) (DeFronzo et al., 2005) 10 lg, 5 lg, and placebo (as add on to metformin & sulfonylurea) (Kendall et al., 2005) Liraglutide 1.8 mg & 1.2 mg (as add on to metformin, vs sitagliptin) (Pratley et al., 2010) (As add on to metformin + Rosiglitazone vs placebo) (Zinman et al., 2009) (As add on to metformin + glimepiride, vs insulin glargine) (Russell-Jones et al., 2009) (As add on to metformin + sulfonyl urea, vs exenatide) (Buse et al., 2009)
1.5 & 1.24, respectively vs 0.9
Comparison of safety studies Drug
Body weight
Hypoglycemia
More reported events
Rare events
Exenatide
Decreased (Bergenstal et al., 2012; Gallwitz et al., 2012b)
Mild episodes (Bergenstal et al., 2012; Buse et al., 2004)
Nausea, diarrhea and upperrespiratory-tract infection (Bergenstal et al., 2012; Gallwitz et al., 2012b) Nausea, vomiting, diarrhea and constipation (Garber et al., 2009; Pratley et al., 2010; Zinman et al., 2009; Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009; Seino et al., 2010; Kaku et al., 2010)
Injection-site erythema, pruritus, urticaria and rash (Buse et al., 2004)
Liraglutide Neutral or decreased (Pratley et al., 2010; Zinman et al., 2009; Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009)
None Garber et al., 2009; Zinman et al., 2009; Buse et al., 2009; Nauck et al., 2009; Marre et al., 2009; Seino et al., 2010; Kaku et al., 2010
Acute pancreatitis and increase in calcitonin level (Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009)
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
6 Sodium glucose co-transporters 2 (SGLT2) inhibitors They represent a new strategy in the treatment of diabetes with a unique mechanism of action. They promote urinary glucose excretion by inhibiting glucose reabsorption from renal tubules and thus decrease plasma glucose levels. A significant proportion of glucose reabsorption is facilitated by SGLT-2, a member of the SGLT family and other members include SGLT-1, 3, 4, 5, and 6. Inhibition of SGLT-2 has been shown to block the body’s capacity to reabsorb glucose via the kidney and thereby reduce blood glucose levels (Isaji, 2007). The roles of other SGLT family members in glycemic control are not well understood. SGLT-1 is highly expressed in the heart and also has an important role in normal intestinal glucose absorption. But its inhibition may lead to diarrhea and severe dehydration, symptoms observed in those with inherited mutations in the SGLT-1 gene. SGLT-3 is expressed in neurons of the small intestine and in neuromuscular junctions of skeletal muscle, transports sodium upon glucose binding, but not capable of monosaccharide transport. SGLT-4, 5 and 6 are expressed in the kidney and play an important role in renal monosaccharide and/or sodium reabsorption (Grempler et al., 2012). SGLT-2 inhibitors fall into 2 classes. C-glucosides (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin and tofogliflozin) and O-glucosides (sergliflozin, remogliflozin, T-1095A and phlorizin). All SGLT inhibitors are structurally similar, with different selectivity profile. Among the inhibitors tested for SGLT-2 over SGLT-1, Empagliflozin was shown to have the highest selectivity with fewer gastrointestinal side effects than the other less selective SGLT-2 inhibitors (Grempler et al., 2012). Preclinical studies and clinical trials have revealed that SGLT2 inhibition offers benefits to diabetic patients by reducing plasma glucose levels, decreasing glucotoxicity and lowering glycosylated hemoglobin levels. Some studies of O-glucosides showed unfavorable pharmacokinetic profile too. The therapeutic potential and safety concerns of these new drugs are currently under clinical development. Summary and discussion All the people never respond in the same way to treatments. Innovative and safe options with better treatment outcomes are greatly needed for the current generation of patients worldwide who are struggling with glycemic control problems, cardiovascular issues and obesity. Traditional oral antidiabetic drugs achieve only limited glycemic control and are accompanied by weight gain or hypoglycemia except for biguanides and alpha-glycosidase inhibitors. Many randomized, double-blind, placebo or active comparator controlled, multicentre trials in patients with T2DM have proved that gliptins produce clinically meaningful reduction of HbA1c and are well tolerated in patients who are inadequately controlled with Metformin, sulfonylureas or glitazones or even with insulin. Unique mechanism of action and oral dosing certainly position gliptins to be a first line option. But high cost and relative lack of long-term safety and efficacy studies like impact on cardiovascular disease are the major constraints at this point. Data from clinical trials suggest that one gliptin is not superior over another with regard to efficacy. But particularly some factors have to be in mind for safe use of each
R.E. George, S. Joseph gliptin. Renal function assessment is needed prior to initiating and periodically during the treatment with sitagliptin. A dosage adjustment is recommended in moderate or severe renal insufficiency and in end-stage renal disease and dialysis cases (Ahre´n, 2010) Also observe patients carefully for signs and symptoms if pancreatitis or a hypersensitivity reaction is suspected. The important clinical concern with vildagliptin is liver enzyme monitoring before and after its initiation since some hepatic enzyme elevation cases were reported with the vildagliptin therapy. While initiating linagliptin, one should be aware of the potential risk for acute pancreatitis (Tradjenta, 2011) Investigators have examined the use of linagliptin in patients with compromised renal function (Sloan et al., 2011; Graefe-Mody et al., 2011) and concluded that dose adjustments based on renal function are not required. Exenatide and liraglutide are subcutaneously injected, peptide GLP-1 receptor agonists that have been shown to improve glycemic control, promote weight loss, and improve some cardiovascular risk markers in patients with T2DM (Klonoff et al., 2008; Aroda and DeYoung, 2011). References Ahre´n, Bo, 2010. Use of DPP-4 inhibitors in type 2 diabetes: focus on Sitagliptin. Diabetes Metab. Syndr. Obes.: Targets Ther. 3, 31–41. Ahren, B., Gomis, R., Standl, E., et al, 2004. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27, 2874–2880. Ahren, B., Pacini, G., Foley, J.E., et al, 2005. Improved meal related beta cell function and insulin sensitivity by the dipeptidyl peptidase 4 inhibitor vildagliptin in Metformin treated patients with type 2 diabetes over 1 year. Diabetes Care 28, 1936–1940. Arjona Ferreira, J.C., Dobs, A., Goldstein, B.J., et al, 2008. Triple combination therapy with sitagliptin metformin and rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetologia 51 (Suppl. 1), S365. Aroda, V.R., DeYoung, M.B., 2011. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgrad. Med. 123, 228–238. Aschner, P., Kipnes, M.S., Lunceford, J.K., et al, 2006. Effect of the dipeptidyl peptidase-4 inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29, 2632–2637. Barzilai, N., Mahoney, E.M., Guo, H., et al, 2009. Sitagliptin is well tolerated and leads to rapid improvement in blood glucose the first days of monotherapy in patients aged 65 years and older with TDM. Diabetes (Suppl. 1), A158. Bergenstal MD, Richard M., Wysham MD, Carol, MacConell PhD, Leigh, et al, 2012. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376, 431–439. Bolli, G., Dotta, F., Rochotte, E., et al, 2008. Efficacy and tolerability of vildagliptin vs. piogitazone when added to metformin: a 24week, randomized, double-blind study. Diabetes Obes. Metab. 10, 82–90. Bosi, E., Camisasca, R.P., Collober, C., et al, 2007. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30, 890–895. Buse Md Phd, John B., Henry Md, Robert R., Han, Jenny, et al, 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy Buse, J.B., Rosenstock, J., Sesti, G., et al, 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47. Chan, J.C.N., Scott, R., Arjona Ferreira, J.C., et al, 2008. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555. Chang, A.M., Jakobsen, G., Sturis, J., et al, 2003. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52, 1786–1791. Charbonnel, B., Karasik, A., Liu, J., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29, 2638–2643. Chiniwala, N., Jabbour, S., 2011. Management of diabetes mellitus in the elderly. Curr. Opin. Endocrinol. Diabetes Obes. 18 (2), 148– 152. DeFronzo, R.A., Ratner, R.E., Han, J., et al, 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100. Degn, K.B., Juhl, C.B., Sturis, J., et al, 2004. One week’s treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduce endogenous glucose release in patients with type 2 diabetes. Diabetes 53, 1187–1194. Dejager, S., Razac, S., Foley, J.E., et al, 2007. Vildagliptin in drugnaive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39, 218–223. Del Prato, S., Barnett, A.H., Huisman, H., et al, 2011. Effect of linagliptin monotherapy on glycaemic control and markers of betacell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 13, 258–267. Dicker, D., 2011. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34, S276–S278. Forst, T., Uhlig-Laske, B., Ring, A., et al, 2010. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabetes Med. 27, 1409–1419. Fujioka, K., 2007. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. JAAPA 20 (12), 3–8. Gallwitz, B., Uhlig-Laske, B., Bhattacharaya, B., 2011. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin. Diabetes 60 (Suppl. 1), 39-LB. Gallwitz, B., Rosenstock, J., Rauch, J., et al, 2012a. Two-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, noninferiority trial. Lancet 380, 475–483. Gallwitz MD, Baptist, Guzman MD, Juan, Dotta MD, Francesco, et al, 2012b. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379, 2270–2278. Garber, A.J., Schweizer, A., Baron, M.A., et al, 2007. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidedione monotherapy: a placebo-controlled study. Diabetes Obes. Metab. 9, 166–174. Garber, A.J., Foley, J.E., Banerji, M.A., et al, 2008. Efficacy of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10 (11), 1047–1056. Garber, A., Henry, R., Ratner, R., et al, 2009. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481.
7
Garber, A., Henry, R.R., Ratner, R., et al, 2011. Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metab. 13, 348–356. Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., et al, 2007. Sitagliptin 036 study group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30, 1979–1987. Gomis, R., Espadero, R.M., Jones, R., et al, 2011. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes. Metab. 13, 653–661. Graefe-Mody, U., Friedrich, C., Port, A., et al, 2011. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diab. Obes. Metab. 13, 939–946. Grempler, R., Thomas, L., Eckhardt, M., et al, 2012. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 (1), 83–90. Hanefeld, M., Herman, G.A., Wu, M., et al, 2007. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr. Med. Res. Opin. 23, 1329–1339. Hermansen, K., Kipnes, M., Luo, E., et al, 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 9, 733–745. Isaji, M., 2007. Sodium glucose cotransporter inhibitors for diabetes. Curr. Opin. Investig. Drugs 8, 285–292. Iwamato, Y., Kashiwagi, A., Yamada, N., et al, 2010. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12 (8), 700–708. Jones, David Russel, Cuddihy, Robert M., Hanefeld, Markolf, et al, 2012. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drugnaive patients with type 2 diabetes (DURATION-4). A 26-week double-blind study. Diabetes Care 35, 252–258. Juhl, C.B., Hollingdal, M., Sturis, J., et al, 2002. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51, 424–429. Kaku, K., Rasmussen, M.F., Clauson, P., et al, 2010. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human GLP-1 analogue liraglutide as add-on to sulfonylurea in Japanese patients with type 2 diabetes. Diab. Obes. Metab. 12, 341–347. Kalra, Sanjay, 2011. Emerging role of dipeptidyl peptidase-IV (DPP4). Inhibitor vildagliptin in the management of type 2 diabetes. JAPI 59, 237–245. Kawamori, R., Inagaki, Araki, E., et al, 2011. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Diabetes 59 (Suppl. 1), 696. Abstract. Kawamori, R., Inagaki, N., Araki, E., et al, 2012. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes. Metab. 14, 348–357. Kendall, David M., Riddle, Matthew C., Rosenstock, Julio, et al, 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091. Kikuchi, M., Abe, N., Kato, M., et al, 2009. Vildagliptin dosedependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 83, 233–240.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
8 Klonoff, D.C., Buse, J.B., Nielsen, L.L., et al, 2008. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275–286. Kothny, W., Schweizer, A., Dickinson, S. et al., 2009. Hepatic safety profile of vildagliptin a new DPP-4 inhibitor for the treatment of type 2 diabetes. 45th Annual Meeting of the European Association for the Study of Diabetes, abstr. 764. Lewin, A.J., Arvay, L., Liu, D., et al, 2010. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Diabetologia 53 (Suppl. 1), S326. Marre, M., Shaw, J., Brandle, M., et al, 2009. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding Rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetes Med. 26, 268–278. McIntosh, C.H., Demuth, H.U., Pospisilik, J.A., et al, 2005. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul. Pept. 128, 159–165. Nauck, M.A., Meininger, G., Sheng, D., et al, 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9, 194–205. Nauck, M., Frid, A., Hermansen, K., et al, 2009. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84–90. Owens, D.R., Swallow, R., Dugi, K.A., et al, 2011. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24-week randomized study. Diabetes Med. 28, 1352–1361. Pi-Sunyer, F.X., Schweizer, A., Mills, D., et al, 2007. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 76, 132–138. Pratley, R.E., Salsali, A., 2007. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 23 (4), 919–931. Pratley, R.E., Jauffret-Kamel, S., Galbreath, E., et al, 2006. Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38, 423–428. Pratley, R.E., Nauck, M., Bailey, T., et al, 2010. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456. Prins, Johannes B., 2008. Incretin mimetics and enhancers: mechanisms of action. Aust. Prescr. 31, 102–104. Raz, I., Hanefeld, M., Xu, L., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49, 2564–2571. Rosenstock, J., Baron, M.A., Dejager, S., et al, 2007a. Comparison of vildagliptin and Rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2), 217–223. Rosenstock, J., Baron, M.A., Camisasca, R.P., et al, 2007b. Efficacy and tolerability of initial combination therapy with vildagliptin and
R.E. George, S. Joseph pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9, 175–185. Rosenstock, Julio., Brazg, Ronald., Andryuk, Paula.J., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 28, 1556– 1568. Russell-Jones, D., Vaag, A., Schmitz, O., et al, 2009. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046– 2055. Scherbaum, W.A., Schweizer, A., Mari, A., et al, 2008. Efficacy and tolerability of vildagliptin in drug naı¨ ve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10, 675– 682. Schweizer, A., Couturier, A., Foley, J.E., et al, 2007. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naı¨ ve patients with Type 2 diabetes. Diabetes Med. 24, 955–961. Scott, R., Wu, L., Sanchez, M., et al, 2007. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61, 171–180. Scott, R., Loeys, T., Davies, M.J., et al, 2008. Efficacy and safety of Sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 10, 959–969. Seino, Y., Rasmussen, M.F., Nishida, T., et al, 2010. Efficacy and Safety of the once-daily human GLP-1 analogue, liraglutide, vs. glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 26, 1013–1022. Sloan, L., Newman, J., Sauce, C., et al, 2011. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes 60 (Suppl. 1), 24–28. Stonehouse, A.H., Darsow, T., Maggs, D.G., 2012. Incretin-based therapies. J. Diabetes 4 (1), 55–67. Taskinen, M.R., Rosenstock, J., Tamminen, I., et al, 2011. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebocontrolled study. Diabetes Obes. Metab. 13, 65–74. Tradjenta (linagliptin) [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc.; 2011. Vilsboll, Tina, Zdravkovic, Milan, Le-Thi, Tu, 2007. Liraglutide, a long acting human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care 30, 1608–1610. Vilsboll, T., Rosenstock, J.M., Yki-Ja¨rvinen, H., et al, 2010. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 12, 167–177. Zinman, B., Gerich, J., Buse, J.B., et al, 2009. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224–1230.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
King Saud University
Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com
REVIEW
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy Regin Elsa George, Siby Joseph
*
Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India Received 8 April 2013; accepted 17 May 2013
KEYWORDS Gliptins; Dipetidyl peptidase inhibitors; Glucagon like peptide
Abstract Diabetes resulting from both genetic and lifestyle factors causes high insulin deficiency or its resistance. As hyperglycemia and decreased insulin secretion and/or its sensitivity appear to be the primary defects associated with diabetes, available treatments focus on reducing those defects. A novel approach of treatment is to target the incretin mimetic hormones, which are secreted by intestinal cells in response to food intake, provoking glucose-dependent insulin secretion from the pancreas. Efficacy and safety studies of dipetidyl peptidase inhibitors (DPP-IV), sitagliptin, vildagliptin and linagliptin provide similar improvements in HbA1c levels when compared with metformin, sulfonylureas or glitazones without contributing to weight gain and hypoglycemia. Caution is required when choosing the gliptin in people with renal or hepatic impairment and with a risk of pancreatitis. The glucagon like peptide (GLP-1) analogues Exenatide and Liraglutide also have positive impact on glycemic control especially when used as a combination therapy. Another upcoming approach is using sodium-glucose co transporter two inhibitors in kidney, by exploring pathophysiology of renal glucose re absorption in the proximal tubule. ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Introduction Even though diabetes is not a new born disease with a history since 1552 its prevalence is increasing day by day. As in other * Corresponding author. Tel.: +91 9961312691. E-mail address: [email protected] (S. Joseph). Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
diseases newer drugs are getting added up and some become outdated or withdrawn. Even the most commonly used oral hypoglycemic agent (OHA) metformin is found to be ineffective in the long-term therapy for many patients. Sulfonylureas are used in case of patients who are not responding to metformin. But they can put patients at an increased risk of hypoglycemia, weight gain, heart attacks and strokes. Glitazones are also associated with cardiovascular risks. To avoid such pitfalls and to improve glycemic control with minimum side effects new therapeutic approaches are developed. Dipeptidyl peptidase (DPP)-4 inhibitors, which enhance postprandial levels of the incretin hormones glucagon like peptide (GLP)-1
1319-0164 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. http://dx.doi.org/10.1016/j.jsps.2013.05.005
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
2 and glucose-dependent insulinotropic polypeptide (GIP), are newer therapeutic options with minimal side effects (Dicker, 2011). The revised consensus algorithm accounts for the introduction of incretin-based therapies into clinical practice. The algorithm was authored in 2009 by the American Diabetes Association and European Association for the Study of Diabetes for the initiation and adjustment of therapy in Type 2 diabetes. The incretin hormones are gut borne and have clinically meaningful effects on glucose homeostasis, particularly in the postprandial period. So according to the algorithm their use can be emphasized in cases of hypoglycemia and increased body weight. Also 66% of the b-cell response during post prandial period is due to the incretin effect. The foundation of incretin-based therapies is to target this newly recognized feature of diabetes pathophysiology, resulting in sustained and powerful glycemic control and body weight control (Stonehouse et al., 2012; McIntosh et al., 2005). The incretins are peptide hormones released into the circulation, in response to luminal nutrients, minutes after a meal. In humans, the major incretins are glucagon-like peptide-1 (GLP-1) secreted by the L cells in the ileum and colon and glucose-dependent insulinotropic polypeptide (GIP) secreted by the K cells in the duodenum. Hormonal effects on multiple organs are found to be exhibited by both GLP-1 and GIP and stimulate insulin secretion in a glucose-dependent manner along with appetite suppression and delayed gastric emptying. As a result of these combined effects, significant contribution has been made for the control of postprandial glucose resulting in a better glycemic control with relatively low risk of hypoglycemia. (Prins, 2008) The incretins are predominant gut borne mediators of insulin release, and GLP-1 deals with glucagon suppression. GLP-1 represents a clinically better therapeutic option over GIP as its insulinotropic effects are preserved in type 2 DM while GIP activity is impaired (Fujioka, 2007). However both incretins are rapidly inactivated in vivo by the enzyme DPP-IV. Two approaches considered to enhance the incretin effect in type 2 diabetes are to either administer GLP-1 receptor agonists that are resistant to cleavage by DPP4 or to inhibit DPP4 enzyme activity. These pharmacological approaches thereby effectively increase the half-life and circulating levels of the incretins (Prins, 2008).
R.E. George, S. Joseph are clinically used now, given as subcutaneous injection. Formulation developments are on going to check whether long-acting once-weekly injections are possible. Exendin, the clinical formulation of exenatide is a potent activator of the GLP-1 receptor with almost 50% homology to GLP-1, while liraglutide maintains normal activity at the GLP-1 receptor. Both are resistant to cleavage by DPP4 and have a long circulating half-life (Prins, 2008). Dipeptidyl-peptidase IV inhibitors Dipeptidyl-peptidase (DPP) IV is a ubiquitous enzyme that is responsible for the inactivation of both incretin hormones GLP-1 and GIP. DPP IV inhibitors are FDA approved oral medications in type 2 diabetes, which inhibit dipeptidyl peptidase-4 thereby increase circulating concentrations of incretin hormones and provide glycemic control with improved islet cell function (Pratley and Salsali, 2007) and by this mechanism of action they allow GLP1 to stay in the body for longer time which improves control of glucose as well as reduce appetite. They help the pancreas to secrete insulin in glucose dependent manner in post-prandial period and thereby reducing dramatic episodes of blood sugar spikes (Stonehouse et al., 2012) Also they are well tolerated, carry a low risk of hypoglycemia and weight gain (Stonehouse et al., 2012; Pratley and Salsali, 2007). Another new approach is the use of sodium glucose co transporter-2 inhibitors which are in the phase III studies for the treatment of type 2 diabetes. Several specific SGLT2 inhibitors currently under development include dapagliflozin, canagliflozin, empagliflozin, ipragliflozin and tofogliflozin. They work independently and inhibit glucose re-absorption from the glomerular filtrate. Reduced renal threshold for glucose, glycosuria and net calorie loss are the results. Trials regarding long-term outcomes are ongoing (Isaji, 2007; Grempler et al., 2012). In the present article, we discuss the attributes of new treatment strategies of diabetes and an attempt has been made to compare and elaborate various aspects of incretin based therapies including their efficacy and adverse reactions focused on GLP1 agonists and commonly used gliptins-vildagliptin, Sitagliptin and linagliptin. Comparison of various efficacy studies of Sitagliptin, Vildagliptin and Linagliptin
Incretin-analogue based therapies Glucagon-like peptide 1 (GLP-1) analogues are the foundation of incretin-based therapies and the main advantage is that they can be used as monotherapy, or in combination with other diabetic medications along with diet and exercise in adults with type 2 DM (Chiniwala and Jabbour, 2011) Emerging evidence suggests minimum risk of hypoglycemia with incretin-based treatments except in combination with insulin secretagogues. They also exhibit beneficial effects on cardiovascular and hepatic health, the central nervous system, inflammation and sleep (Stonehouse et al., 2012) The administration of incretin analogues resistant to cleavage by DPP4 was really appreciable. Two drugs exenatide and liraglutide
A large number of clinical studies and extensive clinical experience demonstrate that gliptins provide unique therapeutic benefits that make them ideal for treatment of type 2 diabetes. They are available in combination pills with Metformin. All these medicines have been shown to significantly reduce HbA1c when used as monotherapy and in combination with other traditional agents. But they are comparatively more expensive. Several studies were designed and done to compare these drugs with other OHAs to clarify their efficacy in relation to traditional agents. Various meta analysis were done to study the safety issues also. They are found to be associated with minimum side effects like headache, nausea as well as mild skin reactions.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy
3
Monotherapy Drug
Duration (weeks)
Number of subjects (N) Baseline HbA1c (%)
Reduction in HbA1c (%)
555 743 123 521 741 65
7.7 7.8 7.8 8.1 8 7.7
0.6 0.8 0.7 (Elderly) 0.6 & 0.5, respectively 0.8 & 0.9, respectively 0.6
12 24
70 & 28, respectively 632
8 8.4
24
354
8.4
12 12
279 & 98 291
8 7.4
188 & 192, respectively
7.6
519 & 267, respectively
8.7
0.6 ± 0.2 0.8 ± 0.1,0.8 ± 0.1 & 0.9 ± 0.1, respectively 0.7 ± 0.2, 0.5 ± 0.2 & 0.9 ± 0.2, respectively 0.43 & 0.6, respectively 0.8%, 1.0% & 1.2% respectively (placebo adjusted mean change) <6.5% in 50.8% & 24.2% patients respectively 1.1 & 1.3, respectively
336 & 167, respectively
P 9.0
5 mg OD &10 mg OD vs voglibose 0.2 mg 26 tid (Kawamori et al., 2012)
561
7.63,7.50 & 7.91, respectively
5 mg OD &10 mg OD vs Placebo (Kawamori et al., 2012)
12
–
7.58%, 7.48% and 8.34%, respectively
24
1091
8.8
24
701
8
52
1172
7.5
18
273
7.7
2.07%, 1.57%, 1.30%, 0.99% & 0.83%, respectively (placebo subtracted change) <7% in 47% & 18.3% patients respectively 0.67 in both (63% and 59% patients respectively) 0.7 & 0.8, respectively
24
441
8.3
0.89
Vildagliptin 50 mg OD (Ahren et al., 2004) 12 50 mg OD vs placebo (Ahren et al., 2005) 52
107 31& 26, respectively
7.7 ± 0.1 7.7
50 mg OD & 50 mg BID vs Placebo (Bosi 24 et al., 2007)
n = 177, 185 and 182, respectively
7.5–11%
50 mg BID vs 30 mg OD pioglitazone (Bolli et al., 2008)
295 & 281, respectively
7.5–11%
0.6 ± 0.1 1.0 ± 0.2% (between group difference) 0.7 ± 0.1% & 1.1 ± 0.1%, respectively (between group difference) 0.9 & 1.0, respectively
524 & 177, respectively
8.1
0.49 & +0.15, respectively
777 & 775, respectively
7.69
0.16 & 0.36, respectively
Sitagliptin 100 mg (Hanefeld et al., 2007; Scott et al., 12 2007; Barzilai et al., 2009) 100 mg & 200 mg (Raz et al., 2006) 24 18 100 mg & 200 mg (Aschner et al., 2006) 24 50 mg (moderate renal insufficiency) 54 25 mg (severe insufficiency) (Chan et al., 2008) Vildagliptin 25 mg BD vs Placebo (Pratley et al., 2006) 50 mg BID, 50 mg OD & 100 mg OD (Dejager et al., 2007) 50 mg BID,50 mg OD & 100 mg OD (PiSunyer et al., 2007) 50 mg & 100 mg (Kalra, 2011) 10 mg, 25 mg & 50 mg BID vs Placebo (Kikuchi et al., 2009)
50 mg BID compared with voglibose 12 (Iwamato et al., 2010) 100 mg compared with rosiglitazone 8 mg 24 (Rosenstock et al., 2007a) Linagliptin 5MG vs Placebo (Del Prato et al., 2011) 24
As add on to metformin Sitagliptin 100 mg + metformin 2G BD, 100 mg + metformin 1G BD, metformin 2G BD, metformin 1G BD, 100 mg OD & placebo (Goldstein et al., 2007) 100 mg vs Placebo (Charbonnel et al., 2006) 100 mg vs 5 mg (Glipizide) (Nauck et al., 2007) 100 mg vs 8 mg (Rosiglitazone) (Scott et al., 2008) 100 mg (As add on to metformin + glimepiride) (Hermansen et al., 2007)
24
Linagliptin Compared with Placebo (Taskinen et al., 24 2011) Compared with glimepiride (Gallwitz 2 year et al., 2012a)
1.01% (placebo adjusted reduction) 0.32% & 0.39%, respectively (adjusted mean difference) 0.87% & 0.88% respectively (adjusted mean difference)
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
4
R.E. George, S. Joseph
Monotherapy Drug
Duration (weeks)
Number of subjects (N) Baseline HbA1c (%)
Reduction in HbA1c (%)
333
793 & 265, respectively
8.2%, 8.5%, 8.4%, 8.2%, and 8.4%, respectively 7–10%
0.4,0.73,0.67 & 0.9 respectively (treatment difference vs placebo) 0.72 & 0.1, respectively
6 MONTH
441
8.3
0.7
24
515
7.5–11
0.6 ± 0.1%, & 0.7 ± 0.1%, respectively (between group difference)
161 & 84, respectively
8.6
0.47 (Placebo adjusted change)
175 & 178, respectively
8.1 & 8, respectively
7.2 & 7.8, respectively (HbA1c at end point)
463
8.7
0.8, 1.0 & 0.3, respectively
150 & 157, respectively
8.7
1.1 & 1.4, respectively
146 & 139, respectively
8.7
1.9 & 1.7, respectively
24
259 & 130, respectively
8.6 & 8.58, respectively 1.25 & 0.75, respectively
Body weight Neutral (monotherapy) Increasing (With insulin and sulfonylureas) (Scott et al., 2007; Raz et al., 2006; Rosenstock et al., 2007a; Charbonnel et al., 2006; Hermansen et al., 2007; Arjona Ferreira et al., 2008) Neutral (Bosi et al., 2007; Bolli et al., 2008; Garber et al., 2007; Pratley et al., 2006; Scherbaum et al., 2008; Schweizer et al., 2007) Neutral or decreased (monotherapy) Del Prato et al., 2011; Taskinen et al., 2011; Forst et al., 2010; Owens et al., 2011; Lewin et al., 2010; Kawamori et al., 2011 Increasing (with glitazones) Gomis et al., 2011
Hypoglycemia None (monotherapy) (Barzilai et al., 2009; Raz et al., 2006; Rosenstock et al., 2007a; Rosenstock et al.) Increasing (with insulin and sulfonylureas) (Nauck et al., 2007; Hermansen et al., 2007; Vilsboll et al., 2010)
More reported events Headache, upper respiratory tract infection, nasopharyngitis. (Chan et al., 2008)
Rare events Pancreatitis, hypersensitivity reactions (Ahre´n, 2010)
None (monotherapy) Nausea, headache Increasing (with insulin) nasopharyngitis, Kalra, 2011 dizziness, cough, constipation (Pratley et al., 2006; Scherbaum et al., 2008) Increasing (with insulin, Urticaria, angioedema sulfonylureas and insulin or bronchial secretagogues) (Forst hyperreactivity (Del et al., 2010; Owens et al., Prato et al., 2011; 2011; Lewin et al., 2010; Taskinen et al., 2011; Gallwitz et al., 2011) Forst et al., 2010; Owens et al., 2011; Gomis et al., 2011; Tradjenta, 2011)
Mild liver enzyme elevation (Kothny et al., 2009)
(As add on to metformin ± OAD) 1 mg, 12 5 mg, 10 mg vs Glimepiride (1–3 mg) or Placebo (Forst et al., 2010) (As add on to metformin + sulfonylurea) 24 5 mg vs Placebo (Owens et al., 2011) As add on to sulfonylurea Sitagliptin 100 mg (Hermansen et al., 2007) Vildagliptin 50 mg OD, BID vs 4 mg (Glimepiride + Placebo) (Garber et al., 2008)
Linagliptin 5 mg OD vs Placebo (Lewin et al., 2010) 18 As add on to glitazones Sitagliptin Compared with placebo (Rosenstock et al.)
24
Vildagliptin 50 mg OD, BD vs 45 mg 24 Pioglitazone + Placebo (Garber et al., 2007) 100 mg OD vs 30 mg Pioglitazone OD) 24 (Rosenstock et al., 2007b 100 mg + 30 mg Pioglitazone & 24 50 mg + 15 mg Pioglitazone (Rosenstock et al., 2007b) Linagliptin 5 mg or Placebo (Gomis et al., 2011) Comparison of safety studies Drug Sitagliptin
Vildagliptin
Linagliptin
-
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy EXENATIDE: Exenatide is the first drug that mimics the activity of incretins, the natural glucoregulatory peptides. In April 2005 it was approved by the US FDA as an adjunctive therapy in patients with type 2 diabetes. Exenatide is a subcutaneously injected, peptide GLP-1 receptor agonist that has been shown to improve glycemic control, promote weight loss, and improve some cardiovascular risk markers in patients with T2DM (Klonoff et al., 2008; Aroda and DeYoung, 2011). LIRAGLUTIDE: Liraglutide is another glucagon-like-peptide-1 (GLP-1) receptor agonist, taken as once daily injection. It was approved by FDA on January 25, 2010. It is designed not only to improve 24-h glycemic control in a glucose-
5
dependent manner by increasing insulin secretion and decreasing glucagon secretion (Chang et al., 2003; Degn et al., 2004) but also accompanied by a delay in gastric emptying and weight loss (Juhl et al., 2002). Many researchers have demonstrated that both exenatide and liraglutide are well tolerated and produce clinically meaningful reduction of HbA1c when used alone and in combination with other drugs. Comparison of various efficacy studies of exenatide and liraglutide
Monotherapy Dose
Duration
No. of patients
Reduction in HbA1c (%)
Exenatide 2 mg once weekly vs 100 mg Sitagliptin or 45 mg Pioglitazone (Bergenstal et al., 2012)
26
160, 166 & 165, respectively
0.6 & 0.3, respectively (treatment difference of exenatide vs Sitagliptin or Pioglitazone)
Once weekly vs metformin, pioglitazone and Sitagliptin (Jones et al., 2012)
26
–
1.53, 1.48, 1.63 & 1.15, respectively
Liraglutide 1.2 mg & 1.8 mg vs Glimepiride (Garber et al., 2009) 1.2 mg & 1.8 mg vs Glimepiride 8 mg (Garber et al., 2011) 0.65 mg, 1.25 mg, 1.90 mg & Placebo (Vilsboll et al., 2007)
52 2 year 14
746 – –
0.84%, 1.14% & 0.51%, respectively 0.9, 1.1 & 0.6, respectively 0.98, 1.40, 1.45 & +0.29, respectively
30
377
30
272
30
733
0.86 ± 0.11%, 0.46 ± 0.12%, and 0.12 ± 0.09%, respectively 0.78 ± 0.10, 0.40 ± 0.11 & +0.08 ± 0.10 0.8 ± 0.1, 0.6 ± 0.1 & +0.2 ± 0.1, respectively
26 26
225,221 & 219, respectively 533
1.5% ± 0.1%vs 1.5% ± 0.1%
26
581
1.33% vs 1.09%
26
233 & 231, respectively
1.12% vs 0.79%, respectively
As combination therapy Exenatide 10 lg, 5 lg, and placebo (as add on to sulfonyl urea) (Buse et al., 2004) 10 lg, 5 lg, and placebo (as add on to metformin) (DeFronzo et al., 2005) 10 lg, 5 lg, and placebo (as add on to metformin & sulfonylurea) (Kendall et al., 2005) Liraglutide 1.8 mg & 1.2 mg (as add on to metformin, vs sitagliptin) (Pratley et al., 2010) (As add on to metformin + Rosiglitazone vs placebo) (Zinman et al., 2009) (As add on to metformin + glimepiride, vs insulin glargine) (Russell-Jones et al., 2009) (As add on to metformin + sulfonyl urea, vs exenatide) (Buse et al., 2009)
1.5 & 1.24, respectively vs 0.9
Comparison of safety studies Drug
Body weight
Hypoglycemia
More reported events
Rare events
Exenatide
Decreased (Bergenstal et al., 2012; Gallwitz et al., 2012b)
Mild episodes (Bergenstal et al., 2012; Buse et al., 2004)
Nausea, diarrhea and upperrespiratory-tract infection (Bergenstal et al., 2012; Gallwitz et al., 2012b) Nausea, vomiting, diarrhea and constipation (Garber et al., 2009; Pratley et al., 2010; Zinman et al., 2009; Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009; Seino et al., 2010; Kaku et al., 2010)
Injection-site erythema, pruritus, urticaria and rash (Buse et al., 2004)
Liraglutide Neutral or decreased (Pratley et al., 2010; Zinman et al., 2009; Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009)
None Garber et al., 2009; Zinman et al., 2009; Buse et al., 2009; Nauck et al., 2009; Marre et al., 2009; Seino et al., 2010; Kaku et al., 2010
Acute pancreatitis and increase in calcitonin level (Russell-Jones et al., 2009; Nauck et al., 2009; Marre et al., 2009)
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
6 Sodium glucose co-transporters 2 (SGLT2) inhibitors They represent a new strategy in the treatment of diabetes with a unique mechanism of action. They promote urinary glucose excretion by inhibiting glucose reabsorption from renal tubules and thus decrease plasma glucose levels. A significant proportion of glucose reabsorption is facilitated by SGLT-2, a member of the SGLT family and other members include SGLT-1, 3, 4, 5, and 6. Inhibition of SGLT-2 has been shown to block the body’s capacity to reabsorb glucose via the kidney and thereby reduce blood glucose levels (Isaji, 2007). The roles of other SGLT family members in glycemic control are not well understood. SGLT-1 is highly expressed in the heart and also has an important role in normal intestinal glucose absorption. But its inhibition may lead to diarrhea and severe dehydration, symptoms observed in those with inherited mutations in the SGLT-1 gene. SGLT-3 is expressed in neurons of the small intestine and in neuromuscular junctions of skeletal muscle, transports sodium upon glucose binding, but not capable of monosaccharide transport. SGLT-4, 5 and 6 are expressed in the kidney and play an important role in renal monosaccharide and/or sodium reabsorption (Grempler et al., 2012). SGLT-2 inhibitors fall into 2 classes. C-glucosides (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin and tofogliflozin) and O-glucosides (sergliflozin, remogliflozin, T-1095A and phlorizin). All SGLT inhibitors are structurally similar, with different selectivity profile. Among the inhibitors tested for SGLT-2 over SGLT-1, Empagliflozin was shown to have the highest selectivity with fewer gastrointestinal side effects than the other less selective SGLT-2 inhibitors (Grempler et al., 2012). Preclinical studies and clinical trials have revealed that SGLT2 inhibition offers benefits to diabetic patients by reducing plasma glucose levels, decreasing glucotoxicity and lowering glycosylated hemoglobin levels. Some studies of O-glucosides showed unfavorable pharmacokinetic profile too. The therapeutic potential and safety concerns of these new drugs are currently under clinical development. Summary and discussion All the people never respond in the same way to treatments. Innovative and safe options with better treatment outcomes are greatly needed for the current generation of patients worldwide who are struggling with glycemic control problems, cardiovascular issues and obesity. Traditional oral antidiabetic drugs achieve only limited glycemic control and are accompanied by weight gain or hypoglycemia except for biguanides and alpha-glycosidase inhibitors. Many randomized, double-blind, placebo or active comparator controlled, multicentre trials in patients with T2DM have proved that gliptins produce clinically meaningful reduction of HbA1c and are well tolerated in patients who are inadequately controlled with Metformin, sulfonylureas or glitazones or even with insulin. Unique mechanism of action and oral dosing certainly position gliptins to be a first line option. But high cost and relative lack of long-term safety and efficacy studies like impact on cardiovascular disease are the major constraints at this point. Data from clinical trials suggest that one gliptin is not superior over another with regard to efficacy. But particularly some factors have to be in mind for safe use of each
R.E. George, S. Joseph gliptin. Renal function assessment is needed prior to initiating and periodically during the treatment with sitagliptin. A dosage adjustment is recommended in moderate or severe renal insufficiency and in end-stage renal disease and dialysis cases (Ahre´n, 2010) Also observe patients carefully for signs and symptoms if pancreatitis or a hypersensitivity reaction is suspected. The important clinical concern with vildagliptin is liver enzyme monitoring before and after its initiation since some hepatic enzyme elevation cases were reported with the vildagliptin therapy. While initiating linagliptin, one should be aware of the potential risk for acute pancreatitis (Tradjenta, 2011) Investigators have examined the use of linagliptin in patients with compromised renal function (Sloan et al., 2011; Graefe-Mody et al., 2011) and concluded that dose adjustments based on renal function are not required. Exenatide and liraglutide are subcutaneously injected, peptide GLP-1 receptor agonists that have been shown to improve glycemic control, promote weight loss, and improve some cardiovascular risk markers in patients with T2DM (Klonoff et al., 2008; Aroda and DeYoung, 2011). References Ahre´n, Bo, 2010. Use of DPP-4 inhibitors in type 2 diabetes: focus on Sitagliptin. Diabetes Metab. Syndr. Obes.: Targets Ther. 3, 31–41. Ahren, B., Gomis, R., Standl, E., et al, 2004. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27, 2874–2880. Ahren, B., Pacini, G., Foley, J.E., et al, 2005. Improved meal related beta cell function and insulin sensitivity by the dipeptidyl peptidase 4 inhibitor vildagliptin in Metformin treated patients with type 2 diabetes over 1 year. Diabetes Care 28, 1936–1940. Arjona Ferreira, J.C., Dobs, A., Goldstein, B.J., et al, 2008. Triple combination therapy with sitagliptin metformin and rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetologia 51 (Suppl. 1), S365. Aroda, V.R., DeYoung, M.B., 2011. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgrad. Med. 123, 228–238. Aschner, P., Kipnes, M.S., Lunceford, J.K., et al, 2006. Effect of the dipeptidyl peptidase-4 inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29, 2632–2637. Barzilai, N., Mahoney, E.M., Guo, H., et al, 2009. Sitagliptin is well tolerated and leads to rapid improvement in blood glucose the first days of monotherapy in patients aged 65 years and older with TDM. Diabetes (Suppl. 1), A158. Bergenstal MD, Richard M., Wysham MD, Carol, MacConell PhD, Leigh, et al, 2012. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376, 431–439. Bolli, G., Dotta, F., Rochotte, E., et al, 2008. Efficacy and tolerability of vildagliptin vs. piogitazone when added to metformin: a 24week, randomized, double-blind study. Diabetes Obes. Metab. 10, 82–90. Bosi, E., Camisasca, R.P., Collober, C., et al, 2007. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30, 890–895. Buse Md Phd, John B., Henry Md, Robert R., Han, Jenny, et al, 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy Buse, J.B., Rosenstock, J., Sesti, G., et al, 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47. Chan, J.C.N., Scott, R., Arjona Ferreira, J.C., et al, 2008. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555. Chang, A.M., Jakobsen, G., Sturis, J., et al, 2003. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52, 1786–1791. Charbonnel, B., Karasik, A., Liu, J., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29, 2638–2643. Chiniwala, N., Jabbour, S., 2011. Management of diabetes mellitus in the elderly. Curr. Opin. Endocrinol. Diabetes Obes. 18 (2), 148– 152. DeFronzo, R.A., Ratner, R.E., Han, J., et al, 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100. Degn, K.B., Juhl, C.B., Sturis, J., et al, 2004. One week’s treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduce endogenous glucose release in patients with type 2 diabetes. Diabetes 53, 1187–1194. Dejager, S., Razac, S., Foley, J.E., et al, 2007. Vildagliptin in drugnaive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39, 218–223. Del Prato, S., Barnett, A.H., Huisman, H., et al, 2011. Effect of linagliptin monotherapy on glycaemic control and markers of betacell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 13, 258–267. Dicker, D., 2011. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34, S276–S278. Forst, T., Uhlig-Laske, B., Ring, A., et al, 2010. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabetes Med. 27, 1409–1419. Fujioka, K., 2007. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. JAAPA 20 (12), 3–8. Gallwitz, B., Uhlig-Laske, B., Bhattacharaya, B., 2011. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin. Diabetes 60 (Suppl. 1), 39-LB. Gallwitz, B., Rosenstock, J., Rauch, J., et al, 2012a. Two-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, noninferiority trial. Lancet 380, 475–483. Gallwitz MD, Baptist, Guzman MD, Juan, Dotta MD, Francesco, et al, 2012b. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379, 2270–2278. Garber, A.J., Schweizer, A., Baron, M.A., et al, 2007. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidedione monotherapy: a placebo-controlled study. Diabetes Obes. Metab. 9, 166–174. Garber, A.J., Foley, J.E., Banerji, M.A., et al, 2008. Efficacy of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10 (11), 1047–1056. Garber, A., Henry, R., Ratner, R., et al, 2009. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481.
7
Garber, A., Henry, R.R., Ratner, R., et al, 2011. Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metab. 13, 348–356. Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., et al, 2007. Sitagliptin 036 study group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30, 1979–1987. Gomis, R., Espadero, R.M., Jones, R., et al, 2011. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes. Metab. 13, 653–661. Graefe-Mody, U., Friedrich, C., Port, A., et al, 2011. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diab. Obes. Metab. 13, 939–946. Grempler, R., Thomas, L., Eckhardt, M., et al, 2012. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 (1), 83–90. Hanefeld, M., Herman, G.A., Wu, M., et al, 2007. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr. Med. Res. Opin. 23, 1329–1339. Hermansen, K., Kipnes, M., Luo, E., et al, 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 9, 733–745. Isaji, M., 2007. Sodium glucose cotransporter inhibitors for diabetes. Curr. Opin. Investig. Drugs 8, 285–292. Iwamato, Y., Kashiwagi, A., Yamada, N., et al, 2010. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12 (8), 700–708. Jones, David Russel, Cuddihy, Robert M., Hanefeld, Markolf, et al, 2012. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drugnaive patients with type 2 diabetes (DURATION-4). A 26-week double-blind study. Diabetes Care 35, 252–258. Juhl, C.B., Hollingdal, M., Sturis, J., et al, 2002. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51, 424–429. Kaku, K., Rasmussen, M.F., Clauson, P., et al, 2010. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human GLP-1 analogue liraglutide as add-on to sulfonylurea in Japanese patients with type 2 diabetes. Diab. Obes. Metab. 12, 341–347. Kalra, Sanjay, 2011. Emerging role of dipeptidyl peptidase-IV (DPP4). Inhibitor vildagliptin in the management of type 2 diabetes. JAPI 59, 237–245. Kawamori, R., Inagaki, Araki, E., et al, 2011. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Diabetes 59 (Suppl. 1), 696. Abstract. Kawamori, R., Inagaki, N., Araki, E., et al, 2012. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes. Metab. 14, 348–357. Kendall, David M., Riddle, Matthew C., Rosenstock, Julio, et al, 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091. Kikuchi, M., Abe, N., Kato, M., et al, 2009. Vildagliptin dosedependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 83, 233–240.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005
8 Klonoff, D.C., Buse, J.B., Nielsen, L.L., et al, 2008. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275–286. Kothny, W., Schweizer, A., Dickinson, S. et al., 2009. Hepatic safety profile of vildagliptin a new DPP-4 inhibitor for the treatment of type 2 diabetes. 45th Annual Meeting of the European Association for the Study of Diabetes, abstr. 764. Lewin, A.J., Arvay, L., Liu, D., et al, 2010. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Diabetologia 53 (Suppl. 1), S326. Marre, M., Shaw, J., Brandle, M., et al, 2009. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding Rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetes Med. 26, 268–278. McIntosh, C.H., Demuth, H.U., Pospisilik, J.A., et al, 2005. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul. Pept. 128, 159–165. Nauck, M.A., Meininger, G., Sheng, D., et al, 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9, 194–205. Nauck, M., Frid, A., Hermansen, K., et al, 2009. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84–90. Owens, D.R., Swallow, R., Dugi, K.A., et al, 2011. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24-week randomized study. Diabetes Med. 28, 1352–1361. Pi-Sunyer, F.X., Schweizer, A., Mills, D., et al, 2007. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 76, 132–138. Pratley, R.E., Salsali, A., 2007. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 23 (4), 919–931. Pratley, R.E., Jauffret-Kamel, S., Galbreath, E., et al, 2006. Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38, 423–428. Pratley, R.E., Nauck, M., Bailey, T., et al, 2010. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456. Prins, Johannes B., 2008. Incretin mimetics and enhancers: mechanisms of action. Aust. Prescr. 31, 102–104. Raz, I., Hanefeld, M., Xu, L., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49, 2564–2571. Rosenstock, J., Baron, M.A., Dejager, S., et al, 2007a. Comparison of vildagliptin and Rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2), 217–223. Rosenstock, J., Baron, M.A., Camisasca, R.P., et al, 2007b. Efficacy and tolerability of initial combination therapy with vildagliptin and
R.E. George, S. Joseph pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9, 175–185. Rosenstock, Julio., Brazg, Ronald., Andryuk, Paula.J., et al, 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 28, 1556– 1568. Russell-Jones, D., Vaag, A., Schmitz, O., et al, 2009. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046– 2055. Scherbaum, W.A., Schweizer, A., Mari, A., et al, 2008. Efficacy and tolerability of vildagliptin in drug naı¨ ve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10, 675– 682. Schweizer, A., Couturier, A., Foley, J.E., et al, 2007. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naı¨ ve patients with Type 2 diabetes. Diabetes Med. 24, 955–961. Scott, R., Wu, L., Sanchez, M., et al, 2007. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61, 171–180. Scott, R., Loeys, T., Davies, M.J., et al, 2008. Efficacy and safety of Sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 10, 959–969. Seino, Y., Rasmussen, M.F., Nishida, T., et al, 2010. Efficacy and Safety of the once-daily human GLP-1 analogue, liraglutide, vs. glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 26, 1013–1022. Sloan, L., Newman, J., Sauce, C., et al, 2011. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes 60 (Suppl. 1), 24–28. Stonehouse, A.H., Darsow, T., Maggs, D.G., 2012. Incretin-based therapies. J. Diabetes 4 (1), 55–67. Taskinen, M.R., Rosenstock, J., Tamminen, I., et al, 2011. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebocontrolled study. Diabetes Obes. Metab. 13, 65–74. Tradjenta (linagliptin) [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc.; 2011. Vilsboll, Tina, Zdravkovic, Milan, Le-Thi, Tu, 2007. Liraglutide, a long acting human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care 30, 1608–1610. Vilsboll, T., Rosenstock, J.M., Yki-Ja¨rvinen, H., et al, 2010. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 12, 167–177. Zinman, B., Gerich, J., Buse, J.B., et al, 2009. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224–1230.
Please cite this article in press as: George, R.E., Joseph, S. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal (2013), http://dx.doi.org/10.1016/j.jsps.2013.05.005